Azole-echinocandin Combination Therapy for Invasive Aspergillosis

Summary

The goals of this study are 3-fold: First, the main study and the primary endpoint will evaluate if the overall mortality can be decreased with initial azole-echinocandin combination therapy compared with triazole monotherapy in patients with IA and documented voriconazole susceptibility. Second, the study design described will also allow to study several other subpopulations; Indeed, the outcome of the following subgroups will be evaluated as well; a. Patients starting azole monotherapy but who switch to directed therapy when it has become clear that the infection is caused by an azole resistant A. fumigatus. b. patients in which eventually no resistance data become available in relation to the treatment they received. Third, the study will evaluate what the outcome is of patients that turn out to be infected with a triazole resistant A. fumigatus who started with a triazole-echinocandin combination therapy.

Timeline

Start

2021-05-11

Primary completion

2024-05-01

Completion

2024-05-01

Publications

• Lamberink H, Huygens S, Aerts R, Lagrou K, van Leeuwen-Segarceanu E, Lodewyck T, Nieuwenhuizen L, Corsten MF, Moors I, Servais S, De Greef J, Hites M, Demandt A, Schauwvlieghe A, Maertens J, Rijnders B. Superiority Trials in Invasive Aspergillosis: A Harsh Reality Check With the IA-DUET (HOVON502) Trial. Clin Infect Dis. 2025 Feb 24;80(2):367-370. doi: 10.1093/cid/ciae501.

Drugs

Indications